含顺铂两药联合方案治疗晚期乳腺癌的临床观察

目的探讨含顺铂的两药联合方案治疗蒽环类耐药晚期乳腺癌的疗效和不良反应,并与含卡培他滨方案进行对比分析。方法将该科收治的32例蒽环类治疗后复发转移晚期乳腺癌患者分为两组,每组16例。含顺铂组:顺铂联合紫杉醇或多西紫杉醇或长春瑞滨或吉西他滨;含卡培他滨组:卡培他滨联合紫杉醇或多西紫杉醇或长春瑞滨或吉西他滨。均治疗2周期以上,每完成2个周期后进行评价。结果含顺铂组的有效率56.25%(9/16),无疾病进展时间(6.2±3.2)个月,含卡培他滨组的有效率62.50%(10/16),无疾病进展时间6.3±4.1个月,两组差异无统计学意义(P>0.05)。结论含顺铂的两药联合方案治疗晚期乳腺癌疗效好,毒副反应可耐受,安全性好。

Clinical Observation of combination with Cisplatin in the Treatment of Advanced Breast Cancer

Objective The objective of this study was to Observe the efficacy and toxicity of Cisplatin and Capecitabine. Methods 32 cases of advanced breast cancer were studied, and among them, patients received Cisplatin and Capecitabine, the efficacy was evaluated after two cycles. Results In Cisplatin group, the response rate was 56.25%（9/16）,and in Capecitabine group, the response rate was 62.50%（10/16）. The response duration of Cisplatin and Capecitabine groups was 6.2 and 6.3 months respectively. The efficacy and response duration were not significantly different between the two groups（P〉0.05）. Conclusion The Cisplatin group is active in the treatment of advanced breast cancer with tolerant toxicity and security